...
首页> 外文期刊>The Japanese journal of antibiotics >Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria
【24h】

Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--I. Gram-positive bacteria

机译:营销后CEFOZOPAN抗菌活性对各种临床分离株的营销监测 - I。 革兰氏阳性细菌

获取原文
获取原文并翻译 | 示例
           

摘要

As a post-marketing surveillance, the in vitro antibacterial activities of cefozopran (CZOP), an agent of cephems, against various clinical isolates were yearly evaluated and compared with those of other cephems, oxacephems, penicillins, and carbapenems. Changes in the bacterial sensitivity for CZOP were also evaluated with the resistance ratio calculated with breakpoint MIC. Sixteen species (1,913 strains) of Gram-positive bacteria were isolated from the clinical materials annually collected from 1996 to 2000, and consisted of methicillin-susceptible Staphylococcus aureus (MSSA; n = 178), methicillin-resistant S. aureus (MRSA; n = 199), methicillin-susceptible Staphylococcus epidermidis (MSSE; n = 98), methicillin-resistant S. epidermidis (MRSE; n = 164), Staphylococcus haemolyticus (n = 72), Staphylococcus saprophyticus (n = 28), Enterococcus faecalis (n = 206), Enterococcus faecium (n = 91), Enterococcus avium (n = 72), Streptococcus pyogenes (n = 133), Streptococcus agalactiae (n = 138), penicillin-susceptible Streptococcus pneumoniae (PSSP; n = 133), penicillin-intermediate resistant S. pneumoniae (PISP; n = 100), penicillin-resistant S. pneumoniae (PRSP; n = 29), Streptococcus milleri group (n = 135) and Peptostreptococcus spp. (n = 137). CZOP possessed comparable antibacterial activities against MSSA and MSSE to other cephems, and was also effective on MRSE but not on MRSA. An antibacterial activity of CZOP against S. saprophyticus was comparable to or higher than other cephems. CZOP, however, did not indicate an antibacterial activity against S. haemolyticus, just like other cephems. An antibacterial activity of CZOP against E. faecalis was comparable to cefpirome (CPR) and higher than other cephems. No antibacterial activity of CZOP against E. faecium and E. avium was observed, just like other drugs. An antibacterial activity of CZOP against S. pyogenes was as potent as that of cefotiam (CTM), cefepime (CFPM) and CPR, and that against S. agalactiae was also preferable. CZOP and other cephems also had a preferable antibacterial activity against S. milleri group that was most sensitive to benzylpenicillin. An antibacterial activity of CZOP against Peptostreptococcus spp. was preferable but weaker than that of cefazolin, CTM and cefmetazole. The resistance ratio estimated with breakpoint MIC of CZOP was 96.5% in MRSA, 93.1% in PRSP, 60.0% in PISP, 40.3% in S. haemolyticus, 22.3% in E. faecalis, and 15.9% in MRSE. Those resistance ratios were similar to those for CFPM, but E. faecalis showed 90.8% resistance for CFPM. The difference in the resistance ratio of E. faecalis demonstrated that CZOP successfully maintained its antibacterial activity against this species. In conclusion, no remarkable annual change in the antibacterial activities of CZOP against the Gram-positive bacteria was observed. The sensitivities of PISP and PRSP to CZOP, however, was suggested to be decreasing.
机译:作为营销后监测,Cefozoppan(Czop)的体外抗菌活性(Czop)对各种临床分离株进行了每年评估,并与其他Cephems,Oxacephems,青霉素和碳癌群相比。还评估了用断点MIC计算的电阻比评估了Czop细菌敏感性的变化。从1996至2000年的每年收集的临床材料中分离出16种(1,913株)克阳性细菌,并由甲氧西林易感金黄色葡萄球菌(MSSA; N = 178),耐甲氧西林耐金黄色葡萄球菌(MRSA; n = 199),甲氧西林易受葡萄球菌(MSSE; n = 98),耐甲氧西林抗甲氧胞菌(MRSE; N = 164),葡萄球菌血溶素(n = 72),葡萄球菌(n = 28),肠球菌粪便( n = 206),肠球菌饲料(n = 91),肠球菌禽(n = 72),链球菌(n = 133),链球菌胆碱(n = 138),青霉素 - 易感链球菌肺炎(pssp; n = 133),青霉素中间抗性S.肺炎(PISP; N = 100),青霉素抗性S.肺炎(PRSP; n = 29),链球菌米兰组(n = 135)和Peptostrophococcus spp。 (n = 137)。 Czop拥有针对MSSA和MSSE的可比抗菌活性,对其他Cephems,并且在MRSE也有效,但不是MRSA。辛博对嗜酸性腹腔的抗菌活性与其他Cephems相当或高。然而,捷径并未表明对血醇的抗菌活性仅仅像其他Cephems一样。 Czop对E. faecalis的抗菌活性与头孢哌粒(CPR)和高于其他Cephems的抗菌活性。没有观察到E. Faecium和E.Avium的辛泛曲面的抗菌活性,就像其他药物一样。 Czop对S. pyogenes的抗菌活性与Cefotiam(CTM),头孢噻肟(CFPM)和CPR的抗菌活性一样有效,并且对抗S.AlAcactiae也是优选的。 Czop和其他Cephems还针对对苄基彭霉素最敏感的S. Milleri组进行了优选的抗菌活性。曲面对皮骨皮球菌的抗菌活性。优选但弱于Cefazolin,CTM和Cefmetazole。 MRSA在辛博的断点MIC估计的抗性比在PRSP中为96.5%,PISP的93.1%,60.0%,S.Hemolyticus的40.3%,E.粪便中的22.3%,MRSE为15.9%。这些抗性比与CFPM的抗性比相似,但E.粪便对CFPM的抗性显示出90.8%。粪便抗性差异的差异证明,捷径成功地将其对该物种的抗菌活性保持着。总之,观察到曲面曲面抗菌活性的显着年度变化对抗革兰氏阳性细菌。然而,PISP和PRSP对CZOP的敏感性被建议减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号